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Introduction
The specialized lining of the urinary tract, the urothelium, which
extends from the renal pelvis to the urethra, is a source of the 5th
most common cancer, responsible for approximately 3% of all
cancer-related deaths in the United States (Jemal et al., 2004).
In the Western world, cigarette smoking is the most important
risk factor, contributing to approximately 50% of all bladder can-
cers, followed by petrochemical and other industrial exposures.
Bladder stones, chronic indwelling Foley catheters (as is com-
mon in patients with spinal cord injuries), schistosomiasis
(which is especially problematic in Egypt), and chemical irrita-
tions are well-documented risk factors. Chronic use of
cyclophosphamide, and the use of high-dose alkylator therapy,
has led to increased recognition of cancers secondary to the
toxic catabolite acrolein. Urothelial cancer is unique among
noncutaneous carcinomas in that it is the only common epithe-
lial neoplasm that usually presents at a superficial stage which
can be readily examined visually and cytologically for diagnostic
and followup studies. The dual-track concept postulates that
urothelial cancers arise via two distinct but somewhat overlap-
ping pathways: papillary and nonpapillary (Figure 1, Czerniak
and Herz, 1995). 80% to 85% of urothelial cancers are exophyt-
ic papillary lesions, which arise from hyperplastic epithelium.
These tumors tend to recur and only rarely evolve into a higher-
grade, invasive cancer. The balance are nonpapillary and inva-
sive at diagnosis, and arise from severe dysplasia or carcinoma
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Figure 1. Dual tract concept of human
bladder carcinogenesis
The expansion of a preneoplastic clone,
which shows minimal phenotypic deviation
from normal urothelium, is an incipient event
of bladder carcinogenesis. The continuous
growth of such clone results in the develop-
ment of low-grade superficial papillary
tumors. In a nonpapillary pathway, a suc-
cessive subclone of the initial hyperplasia
develops genetic instability with frequent
loss of major tumor suppressors (RB and p53). 
A: Normal urothelium. 
B: Urothelial hyperplasia adjacent to a low-
grade superficial papillary TCC. 
C and D: Low-grade superficial tumor with
features of hyperplasia. 
E: Flat severe intraurothelial dysplasia/carci-
noma in situ adjacent to a high-grade
invasive nonpapillary carcinoma shown in F. 
F: High-grade invasive nonpapillary carc-
inoma. 
G: Flat severe intraurothelial dysplasia/carci-
noma in situ developing in bladder mucosa
adjacent to a low-grade papillary tumor. It is
responsible for switching the pathway and
progression of some low-grade papillary
tumors to high-grade invasive cancers.
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in situ (CIS).The vast majority of invasive bladder cancers occur
in patients without a prior history of papillary tumors.
Molecular genetics
Virtually every newly discovered transforming and tumor sup-
pressor gene has been studied in urothelial cancer (Cordon-
Cardo et al., 1995; Czerniak and Herz, 1995). The human ras
genes represent an important prototypical family of cellular
transforming genes originally identified in the T24 human
urothelial cancer cell line (Reddy et al., 1982).Two mechanisms
for ras gene transformation have been discovered.The most fre-
quent is mutation of codons 12, 13, 59, or 61, which affect the
enzymatic activity of the protein. In the second mechanism,
internal splicing within the last intron mediates ras gene expres-
sion. Mutations of the coding sequence of the H-ras gene, espe-
cially at codon 12, are relatively frequent, appearing in
approximately 30%–40% of urothelial malignancies (Czerniak
et al., 1992). Though concurrent mutations within the splicing
mechanism and the coding sequence resulting in the overex-
pression of the transforming gene product were found exclu-
sively in high-grade and high-stage tumors, they could be
documented in less than 10% of urothelial tumors. The exact
role of the ras genes and their significance as diagnostic mark-
ers of urinary bladder carcinoma are still unclear.
Experimental data and numerous clinical studies indicate that
alterations of both the p53 and RB gene pathways (Shariat et al.,
2004) play a major role in human bladder carcinogenesis (Figure
2). The most frequent alteration involves exons 5–11 of p53 and
the loss of RB gene function (Mark and Jones, 1998).This mecha-
nism was identified in approximately 60% of the human urinary
bladder carcinoma cell lines tested. The second, less frequent
mechanism, observed in approximately 20% of the cell lines, rep-
resents an independent synchronous loss of the tandemly linked
CDKN2a (p16ink4a) and ARF (p19ink4b) in a single step that
inactivates the 9p21 locus and results in transformation and
immortalization of urothelial cells, presumably by indirectly impair-
ing the p53 and RB pathways. A third mechanism, which was also
observed in approximately 20% of cell lines, involved alterations of
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Figure 2. Molecular mechanisms of bladder carcinogenesis
A: Alterations of p53 and RB pathways that may directly or indirectly
involve p53 and RB genes by loss of tandemly linked CDKN2a and ARF
genes play a major role in bladder carcinogenesis. They are typically seen
in a large proportion of clinically aggressive high-grade nonpapillary can-
cers. (From Mark and Jones, 1998. Used with permission.) 
B: Kaplan-Meier analysis of metastasis-free survival of patients with bladder
cancer (n = 181) in relation to the inactivation of RB and p53 pathways. The
inactivation of RB and p53 pathways has a synergistic effect on metastasis-
free survival. (B.C. and W.F.B., unpublished data.)
Figure 3. An example of chromosomal region associated with clonal
expansion of intraurothelial preneoplasia identified by whole organ map-
ping with SNPs
A: Genome sequence map of 2.5 Mb segment telomeric to p53 is shown.
The bars on the left side of the map depict known (long bars) and predict-
ed (short bars) genes. The bars on the right side of the map depict all infor-
mative SNPs identified in the peripheral blood of the same patient. The
chromosomal region subjected to fine mapping is depicted in the chromo-
somal diagram on the left side of the gene sequence map. An area of
allelic loss associated with clonal expansion of preneoplasia is depicted as
a shadowed bar defined by testing of SNPs with loss of polymorphism in the
entire bladder mucosa. 
B: An example of informative SNP showing loss of G/A polymorphism in
mucosal samples corresponding to normal urothelium (NU), low-grade dys-
plasia (LGIN), high-grade dysplasia (HGIN), and invasive bladder cancer
(TCC). 
C: Histologic map of cystectomy showing the distribution of preneoplastic
in situ lesions and invasive cancer. The distribution of allelic loss in the blad-
der mucosa is outlined by the continuous red line and depicts a plaque of
clonally expanding preneoplastic urothelial cells in association with a loss
of approximately 0.1 Mb segment outlined by a shadowed area in A. This
segment contains nine known and three predicted candidate genes that
may provide growth advantage and drive clonal expansion of a preneo-
plastic clone. (B.C. and T.T., unpublished data.)
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p53 in exons 1–4 followed by loss of CDKN2a and ARF function.
Thus, patterns of p53 mutations may be a prerequisite for subse-
quent, distinctive molecular events in other genes such as RB and
CDKN2a and ARF locus (Mark and Jones, 1998).
Recent studies confirm that some molecular events are
common to both pathways of bladder cancer development.
These events precede the development of microscopically rec-
ognizable disease and are antecedent to the involvement of
major tumor suppressors such as RB1 and p53. Mapping stud-
ies have shown that bladder cancer develops in association to
losses of chromosomal regions critical for expansion of in situ
preneoplasia (Figure 3). In general, these regions have mapped
contiguously to the known major tumor suppressor genes, such
as RB1 and p53 (Czerniak et al., 2000).
Preclinical models 
Cell lines
Bladder cancer researchers benefit from the availability of a
large number of human cell lines. Cordon-Cardo’s group com-
pared the expression profiles of 9 of them using cDNA microar-
rays. Importantly, novel targets identified in the screen were
later validated by a tissue microarray of primary TCC’s
(Sanchez-Carbayo et al., 2002).
Transgenic mice 
The uroplakin promoter has been used successfully to create
transgenic mice that recapitulate the dual-track pathways of
human bladder cancer development (Figure 4). In the first, the
uroplakin promoter was used to drive expression of the SV-40
large T antigen in the mouse bladder. This simultaneously inac-
tivates the p53 and Rb pathways, resulting in the emergence of
CIS and highly invasive tumors that share the molecular abnor-
malities and histopathology of the aggressive lesions observed
in humans (Zhang et al., 1999). Alternatively, the uroplakin pro-
moter has also been used to drive expression of mutant Ras or
EGFR in the mouse bladder urothelium. The Ras transgenic
mice developed superficial papillary lesions that only became
invasive when animals were crossed with p53 null mice.
Overexpression of the EGFR similarly resulted in simple urothe-
lial hyperplasia, and animals expressing both mutant Ras and
EGFR were indistinguishable in phenotype from those bearing
mutant Ras alone. However, overexpression of the EGFR con-
verted tumors in the SV-40 low copy number animals into high
grade TCCs.
Xenograft models 
Orthotopic human tumor xenografts have also been developed
that recapitulate the properties of the two major subtypes of
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Figure 4. A mouse model of urothelial carcinogenesis recapitulating dual tract pathogenesis of human bladder cancer
A: Normal mouse urothelium. 
B: The uroplakin promotor was used to drive expression of mutant ras or EGFR, which resulted in urothelial hyperplasia and development of superficial pap-
illary tumor of low histologic grade. 
C and D: Low-grade superficial papillary tumor with features of urothelial hyperplasia developed after overexpression of mutant H-ras. 
E: Whole-mount histologic preparation of mouse bladder showing diffuse involvement of the mucosa by a superficial low-grade papillary tumor. 
F and G: In contrast, the uroplakin driven expression of SV 40 large T antigen simultaneously inactivating p53 and RB pathways resulted in the development
of high-grade in situ neoplasia, which progressed to a high-grade invasive cancer. (Knockout animals were generously provided by Drs. X.R. Wu and T.T.
Sun, Department of Urology, Kaplan Comprehensive Cancer Center, New York University School of Medicine, New York.)
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urothelial cancer. In the first, superficial lesions are created by
direct instillation of human KU-7 cells into the nude mouse blad-
der following gentle trypsinization (Figure 5). Tumors rapidly
form in nearly 100% of the mice (Watanabe et al., 2000). In the
second, human urothelial cancer cells were “recycled” by selec-
tion for orthotopic growth within the bladder wall, resulting in the
isolation of variants that display aggressive local growth and
metastasis.
Molecular epidemiology
Numerous studies have assessed associations between poly-
morphisms of various genes involved in xenobiotic (i.e., drug)
metabolism and bladder cancer risk. However, interpreting such
studies requires a detailed knowledge of the metabolism of par-
ticular carcinogens. For example, in the metabolism of aromatic
amines, a large class of carcinogens implicated in bladder can-
cer, N-acetyltransferase 2 (NAT-2)-mediated N-acetylation is a
detoxification step for some, but an activation step for others
(Rothman et al., 1996).
DNA repair capacity varies substantially within the human
population, and is plausibly related to cancer susceptibility. In
the context of bladder cancer, two variant alleles of the X-ray
repair, cross-complementing group 1 (XRCC1) gene and a vari-
ant allele of XRCC3, are associated with a decreased risk of
bladder cancer. Using a mutagen challenge comet assay to
measure latent genetic instability, Schabath et al. reported a 2-
fold increased risk of bladder cancer in individuals susceptible
to benzo[a]pyrene diol epoxide- (BPDE, a tobacco mutagen)
and γ radiation-induced DNA damage in peripheral blood lym-
phocytes (Schabath et al., 2003), strongly suggesting that indi-
viduals better able to resist or repair DNA damage are less
susceptible to malignant transformation.
Telomeres also contribute to maintaining genetic stability,
and telomere shortening is an early event in carcinogenesis.
Using a novel laser scanning cytometry-based quantitative fluo-
rescence in situ hybridization method to determine telomere
length distribution in individual cells, it was discovered that indi-
viduals with shorter telomeres have a 6-fold elevated risk for
bladder cancer and exhibit a supra-additive interaction between
smoking status and telomere length (Wu et al., 2003).
Diagnosis
The diagnosis of urothelial cancer follows from endoscopic
examination coupled with histologic evaluation of material
obtained by transurethral biopsy. Unfortunately, cystoscopy can
fail to detect the most important indicator of dangerously unsta-
ble urothelium: CIS. Areas of CIS can be visually indistinguish-
able from the surrounding normal bladder. Furthermore,
fluorescence cystoscopy (still an investigational technique)
demonstrates that conventional cystoscopy can miss not only
CIS but small papillary lesions as well.
A variety of biomarkers have been used to enhance the
detection of bladder cancer. The “gold standard” and oldest
such biomarker is urine cytology. Urine cytology can accurately
detect occult CIS, and a positive cytology in absence of a posi-
tive cystoscopy is used as an indication for random bladder
biopsies. A variety of newer markers have been developed that
generally have higher sensitivity but lower specificity than urine
cytology. Tests are being developed to evaluate a variety of pro-
teins including cytokeratins, nuclear matrix proteins (BLCA4),
extracellular matrix proteins (hyaluronic acid and
hyaluronidase), and antiapoptotic proteins (e.g., survivin).
Advances in molecular biology have provided the opportunity to
take advantage of genomic and proteomic changes in cancer
cells to enhance their detection. Microsatellite analysis is
promising and is currently undergoing validation through the
National Cancer Institute Early Detection Research Network
(http://www3.cancer.gov/prevention/cbrg/edrn/).
Therapy
Superficial bladder cancer
Transurethral resection (TUR) is sufficient therapy for most low-
grade noninvasive tumors. The majority of these will recur with-
in a 5-year period, but will rarely invade or result in death from
bladder cancer. The recurrence rate of low-grade TCC is
decreased by a single post-TUR intravesical instillation of
chemotherapy (Sylvester et al., 2004). Although a variety of
intravesical therapies (chemotherapy and immunotherapy) are
used, bacillus Calmette-Guerin (BCG) remains the most effec-
tive intravesical treatment (Bohle et al., 2003). Unfortunately,
although BCG is quite an effective therapy in terms of response
and short-term control, long-term followup studies reveal that
the majority of high-grade invasive cancers eventually recur
(Cookson et al., 1997). Efforts to improve the efficacy of BCG by
adding interferon-α are ongoing (O’Donnell et al., 2001). At this
time, there are no validated markers to predict response to
intravesical therapy; however, proinflammatory cytokines
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Figure 5. Implantation of human bladder
cancer cells into mouse bladder
A: Superficial KU7 human bladder tumor
growing in mouse bladder two weeks after
intravesical installation of cancer cells. 
BD: A KU7 bladder tumor containing the
green fluorescent protein grows in the blad-
der 13 weeks after intravesical installation
of tumor cells. 
E: Pretreatment KU7 bladder tumor growing
two weeks after cell injection. 
F: Marked tumor regression seen three
weeks after a one-hour treatment with
the intravesical installation of an aden-
oviral construct containing a human
interferon α insert. (Modified from
Watanabe et al. [2000]. Used with per-
mission. http://www.nature.com/cgt.)
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released during T1 helper lymphocyte response modulate the
therapeutic effects of BCG (Saint et al., 2002).
Muscle-invasive disease
Patients with muscle invasion (clinical stage T2) have a poten-
tially life-threatening disease. However, the notion that such
patients have a 50% survival is simply not true. In modern sur-
gical series (Cheng et al., 2000), only about 20% of patients
with clinical T2 disease are found to have more advanced
stage at cystectomy, and these patients with higher pathologic
stage do have about a 50% cause-specific survival.
Importantly, however, patients that have pathologically con-
firmed organ-confined bladder cancer have 80% to 85% long-
term disease-free survival with radical cystectomy and pelvic
lymphadenectomy. A subset of patients with muscle invasion
can be treated with less radical therapy. This subset is current-
ly characterized by solitary lesions with only focal muscle inva-
sion, tumors that are relatively small (<5 cm), are completely
resectable by TUR, are located away from the uretero-vesical
junctions and the bladder outlet, and are not associated with
diffuse CIS or hydronephrosis. For these patients, a therapeu-
tic TUR, a partial cystectomy, or chemoradiation may be ade-
quate (Michaelson et al., 2004). Even with these caveats,
however, patients managed with bladder preservation require
long-term surveillance, and many will eventually require cys-
tectomy.
Locally advanced disease
Patients presenting with cancers unlikely to be cured by
surgery alone have improved outcome by the addition of multi-
agent chemotherapy (Grossman et al., 2003). Perioperative
chemotherapy can be given prior to (neoadjuvant) or after
(adjuvant) cystectomy, and limited available data do not sug-
gest a significant difference in outcome based on sequence
(Millikan et al., 2001). Combination chemotherapy is quite
toxic, so that the improved outcome with multimodal therapy is
accompanied by a risk for increased toxicity, and patient selec-
tion is critical.
Unresectable and metastatic disease
For patients with grossly metastatic disease, contemporary
chemotherapy regimens produce reliable symptom palliation
and median survival in the range of 13 to 18 months. Although
few responses are durable, large trials from major centers con-
sistently show about 10% to 15% long-term disease-free sur-
vival after combination chemotherapy. The combination of
methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC)
was introduced 20 years ago (Sternberg et al., 1985), and
there are at least 10 randomized comparisons of MVAC with
other combinations. No incremental improvement from the
results obtained with MVAC has been reported, and currently
reported phase II and phase III results with various combina-
tions incorporating gemcitabine and taxanes (van der Maase et
al., 2000) do not foreshadow improved survival. It is intriguing
that several lines of evidence suggest that bladder cancers
with altered TP53 are more susceptible to chemotherapy. A
national trial to formally test this hypothesis is underway. There
is a pressing need to expand the cytotoxic paradigm.
Unfortunately, despite promising preclinical data, there are no
human data suggesting improved outcome by the integration of
newer, targeted therapies.
Therapeutic prospects
Deregulation of cell cycle and apoptotic pathways via mutation
or altered expression of p53, p21/WAF-1, pRB, p27, and INK4A
(p16) are necessary for uroepithelial transformation. In addition,
members of the erbB family, vascular epidermal growth factor
(VEGF), NFκB, Akt, PTEN, and cyclooxygenase/2 (COX-2), are
also implicated in the progression of the disease (Cote and
Datar, 2003). All of these molecules are potential targets for
novel therapies.
Both EGFR and Her2/neu are highly expressed by urothe-
lial cancer, and Phase II trials evaluating the efficacy of these
growth factor antagonists are ongoing. Recently it was discov-
ered that a small subset of patients with non-small cell lung car-
cinoma who responded favorably to gefitinib harbored an
activating somatic mutation within the tyrosine kinase domain of
the EGFR (Lynch et al., 2004). Screening for this mutation in
bladder cancer may identify appropriate patients for gefitinib
therapy. Recent clinical studies suggest that VEGF overexpres-
sion in prechemotherapy samples from patients with locally
advanced urothelial cancer undergoing cystectomy and
chemotherapy is a strong predictor for recurrence and death
from bladder cancer (Slaton et al., 2004). This observation puts
forward the important hypotheses that VEGF expression is
mechanistically relevant to clinically aggressive bladder cancer
and provides rationale for clinical investigation of interventions
capable of blocking VEGF signaling. Increased prostaglandin
production correlates positively with cancer risk, and COX-2,
the inducible rate-limited enzyme for prostaglandin synthesis, is
upregulated in bladder cancers.Therapeutic inhibitors of COX-2
(NSAIDs) are under active clinical investigation as a chemopre-
ventive agent.
The development of intravesical gene therapy for superficial
bladder cancer has been hindered by limitations in gene deliv-
ery to the urothelium. Various approaches to enhance gene
transfer are under study, including the administration of the
polyamide Syn3, which enhanced adenoviral-mediated gene
transfer of interferon-α gene, resulting in the regression of
established human xenografts growing in athymic nude mice
(Benedict et al., 2004; Figure 5).
Summary
Urothelial cancer is common and has ample lethal potential.
However, most patients present before the disease is clinically
beyond the bladder, and tools to interrogate the biologic poten-
tial of the urothelium would be expected to produce significant
advances in the management of this disease. Likewise, the
combination of available chemotherapy with surgery clearly
results in an improved cure fraction for patients with locally
advanced disease. Thus, significant improvements in overall
mortality could be expected from better patient selection for
systemic therapy and incremental advances in the activity of
systemic therapy.
To this end, the multichannel characterization of genomic
and proteomic features of various clinical phenotypes, including
benefit from existing therapies, dominates current research
directions. In addition, the ready availability of the urothelium
should provide an extremely valuable clinical research tool to
investigate minimal residual disease, gene therapy, and other
novel clinical directions that will be of substantial interest from
the perspective of epithelial cancers generally.
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